Last checked at 20 Apr 2016 07:00
Onzima Ventures PLC
("Onzima" or the "Company")
Filing of Patents by 49%-owned N4 Pharma
Onzima is pleased to announce that N4 Pharma Limited ("N4 Pharma") its 49%-owned investee company has filed a range of 45 patents to allow N4 Pharma to reformulate sildenafil to greatly improve the pharmacological profile of this global drug.
The patents include novel cocrystals of sildenafil discovered by N4. They also include the first tranche of the patents recently acquired from OPAL IP which greatly extend the scope of the reformulation such that N4 Pharma are able to not only improve the onset of action but maintain the level of the drug in its therapeutic window from dose to dose, therefore also extending the drugs length of action.
N4 Pharma CEO Nigel Theobald commented:
"This is a major step forward for N4 Pharma and clearly demonstrates our strategy of securing strong intellectual property that we can then take forward commercially with the right partner.
In effect we are able to combine the onset advantages of Stendra and the long lasting advantages of Cialis into a new reformulation of sildenafil that will give the world's most popular drug for erectile dysfunction a new lease of life with strong long term patent protection.
This is the first example of how we plan to combine the patent skills from OPAL IP with the reformulation skills of N4 pharma and we will seek to repeat this with a number of other well-known drugs.
Our next step for this product is to open discussions with some of the leading formulation and pharmaceutical companies to partner us in bringing this new drug to market"
For further information please contact:
Onzima Ventures PLC Tel: +44 (0) 1732 366 561
Gavin Burnell, Luke Cairns
Nominated Adviser
Cairn Financial Advisers LLP Tel: +44 (0) 20 7148 7900
Sandy Jamieson, Liam Murray
Broker
Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930
Guy Miller, Lucy Williams